Regulatory News
Thursday, December 29, 2016
BRIEF-Cempra receives complete response letter from FDA for solithromycin NDAs
* Cempra receives complete response letter from FDA for
solithromycin NDAs
Read more
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment